Candel Therapeutics, a clinical-stage biopharmaceutical company, announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026. The company focuses on developing multimodal immunotherapies for cancer, with lead candidates aglatimagene besadenovec and linoserpaturev in advanced clinical trials. These therapies have received multiple FDA designations, highlighting their potential to improve treatment outcomes for cancers like prostate, lung, pancreatic, and glioma. The presentation will be webcast and available for replay, offering investors insight into Candel's progress and future plans.
Raymond James raised Johnson & Johnson's price target to $280, signaling a 10% upside from current levels. The boost follows strong Q2 revenue growth in its oncology division, which now accounts for nearly 29% of total revenues, driven by key cancer ...
Easterly Government Properties reported a solid Q2 2026 with a 10% year-over-year revenue increase to $92.4 million and a 5.4% rise in Core FFO per share. The REIT, which leases commercial properties primarily to U.S. government agencies, benefits fr...
Twist Bioscience reported a quarterly loss of $0.56 per share, missing analyst expectations, but achieved strong revenue growth of $118.4 million, a 23% increase year-over-year. This marks the company's 14th consecutive quarter of revenue growth, dri...
Booking Holdings will report its Q2 2026 earnings on August 4, with analysts forecasting revenue of about $7.19 billion, a 5.76% increase year-over-year. Earnings per share (EPS) estimates range from $2.43 to $2.45, reflecting a 10.4% growth supporte...
Versigent PLC, a Swiss company specializing in electrical power systems and EV charging infrastructure, aims for an adjusted EBITDA margin of 12% and $1 billion cumulative free cash flow between 2026 and 2028. The company generates 75% of its revenue...
